The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study.
International medical case reports journal 2023 DOI: 10.2147/imcrj.s395342 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | Immunocompetent male with serologically positive neuropsychiatric Lyme disease |
| Intervention | Psilocybin |
| Dose | microdosed (sub-hallucinogenic) amounts |
| Topics | Psilocybin |
| Keywords | Autoimmune Encephalopathy Mental illness Microdose Neuroinflammation #lymedisease lyme borreliosis Borrelia infection #psychedelics psilocybin Hallucinogens Entheogens #microdosing |
| Citations | 7 |
| Key findings | Microdosed psilocybin was associated with remission of neuropsychiatric symptoms in a patient with Lyme disease who had not tolerated other treatments. |
Abstract
Lyme disease can result in severe neuropsychiatric symptoms that may be resistant to treatment. The pathogenesis of neuropsychiatric Lyme disease is associated with autoimmune induced neuroinflammation. This case report describes an immunocompetent male with serologically positive neuropsychiatric Lyme disease who did not tolerate antimicrobial or psychotropic medications and whose symptoms remitted when he began psilocybin in microdosed (sub-hallucinogenic) amounts. A literature review of its therapeutic benefits reveals that psilocybin is both serotonergic and anti-inflammatory and therefore may offer significant therapeutic benefits to patients with mental illness secondary to autoimmune inflammation. The role of microdosed psilocybin in the treatment of neuropsychiatric Lyme disease and autoimmune encephalopathies warrants further study.